1min snip

The Proof with Simon Hill cover image

New heart disease test you should order | Thomas Dayspring, Md

The Proof with Simon Hill

NOTE

Targeting ApoB and Lp(a) for Cardiovascular Health

Obisetropib shows promise in significantly lowering ApoB levels by 15 to 20% and LP little a by 50 to 60%, suggesting its efficacy rivaling that of Zetimibe and bempedoic acid in reducing major adverse cardiovascular events (MACE). This indicates that a considerable reduction in ApoB may lead to a similar reduction in MACE rates. Additionally, ongoing research on OB-Cetrapib and other compounds suggests potential mechanisms involving the inhibition of apoprotein synthesis. Phase two trials of movalalapine are underway, targeting the binding of apoprotein little a to LDL particles, holding the potential for substantial decreases in LP little a concentrations.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode